Add To Watchlist
Share URL
Gilead Sciences, Inc.
GILD: NasdaqGSLowest reading is at 20 out of 100. All scores are out of 100.
About The Company
CEO
Mr. Daniel Patrick O'Day
Market Cap
187.15 Billion USD
Sector
Healthcare
Website
https://www.gilead.comLast Update
26/09/2026, 10:13:36
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Read More
Strongest readings
- ✔Return on capital employed of 21.23% is above the market average of 10.00%
- ✔Financial health is strong (health score 71 out of 100)
- ✔Altman-Z score of 4.61 sits above the distress range
- ✔Share count has been falling at 0.21% per year
Weakest readings
- ✘Revenue is growing at 2.40% per year while free cashflow is falling
- ✘The current price sits above estimated fair value (margin of safety -78.56%)
- ✘Earnings and cashflow growth is weak (growth score 37 out of 100)
Key Figures
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
Price / earnings (TTM) | N/A | 19.60x | ||
| ✘ | Margin of safety (DCF) | -78.56% | 17.95% | |
| ✘ | Revenue growth (5y average) | 2.40% | 10.97% | |
| ✔ | Dividend yield (TTM) | 2.17% | 1.85% | |
| ✔ | Share count, per year | -0.21% | 0.00% | |
| ✔ | Return on capital employed | 21.23% | 10.00% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Valuation
20 / 100Priced above the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
Price / earnings | N/A | 19.60x | ||
| ✔ | Free cashflow yield | 6.92% | 4.70% | |
| Price / earnings growth | N/A | 1.50x | ||
| Price / book | 15.82x | — | ||
| ✘ | Margin of safety | -78.56% | 17.95% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Estimated intrinsic value of 32.36 USD is below the current price of 150.93 USD
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Estimated Fair Value: 123.6 USD ✘
Current Price: 150.9 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated fair value for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel for the impact this has on longterm investment returns and find a margin of safety you are comfortable with.
Growth
37 / 100Growing more slowly than the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Revenue growth | 2.40% | 10.97% | |
| ✔ | Earnings growth | 24.04% | 14.48% | |
| ✘ | Cashflow growth | -8.24% | 12.35% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✔Revenue growth has improved this year (5.52% against a five year average of 2.40%)
- ✔Free cashflow growth has improved this year
- ✘Revenue is growing at 2.40% per year while free cashflow is falling at 8.24% per year
Health
71 / 100Balance sheet covers its obligations.
Measured on Leverage and capital, Funding and liquidity, Earnings quality.
| Status | Metric | Value | Reading | Threshold |
|---|---|---|---|---|
| ✔ | Altman-Z score | 4.61 | 3.00 | |
| ✔ | Piotroski score | 8.00 | 5.00 | |
| ✘ | Debt / equity | 1.10x | 0.80x | |
| ✔ | Current ratio | 1.55x | 1.00x | |
| ✔ | Interest coverage | 9.79x | 2.50x | |
| ✔ | Free cashflow / debt | 0.38x | 0.15x | |
| ✔ | Debt / capital | 0.52x | 1.00x |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Dividend
65 / 100Covered, with limited headroom.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Dividend yield | 2.17% | 1.85% | |
| ✔ | Dividend growth | 2.17% | 0.00% | |
| ✔ | Payout ratio (earnings) | -125.56% | 40.00% | |
| ✔ | Payout ratio (cashflow) | 31.43% | 65.00% | |
| ✔ | Worst year, last 5 years | 2.42% | -2.00% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Dividend growth has been slowing recently
Management
64 / 100Returns on capital are at or above the market.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Return on equity | 37.48% | 15.00% | |
| ✔ | Return on capital employed | 21.23% | 10.00% | |
| Return on assets | 14.42% | — | ||
| Free cashflow return on capital | 20.03% | — | ||
| ✔ | Return on capital, 5y change | 0.01% | 0.00% | |
| ✔ | Share count, per year | -0.21% | 0.00% | |
| ✔ | Share count, recent | -0.33% | 0.00% | |
| ✘ | Realized buyback return | -74.17% | 0.00% | |
| ✔ | Goodwill erosion / equity | 0.08% | 2.00% | |
| Price volatility, 5 year | 23.55% | — |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Shares were repurchased while the value score was only 20 out of 100
Analysts
not enough data| Status | Metric | Value | Reading | Neutral |
|---|---|---|---|---|
| Analyst opinion score | N/A | 50 |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Financial History
Annual figures across the full reporting history we hold.
Market Peers
GILD
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
See 35+ Years Annual ReportsOther Information
Company Name
Gilead Sciences, Inc.
Currency
USD
Beta
0.35
Vol Avg
6375693
Ceo
Mr. Daniel Patrick O'Day
Cik
0000882095
Cusip
Exchange
NasdaqGS
Full Time Employees
17000
Industry
Drug Manufacturers - General
Sector
Healthcare
Ipo Date
Address
333 Lakeside Drive
City
Foster City
State
CA
Country
United States
Zip
94404
Phone
650 574 3000
Analysis Last Updated
26/09/2026, 10:13:36
Financial data compiled from SEC EDGAR filings and Yahoo Finance.